The U.S. Food and Drug Administration (FDA) has authorized a single booster dose of the Pfizer-BioNTech COVID-19 vaccine bivalent for children six months old through four years of age.
At least two months prior to getting this booster, children must have completed their three-dose primary vaccination series.
Children in that age range who only received the first two doses of the Pfizer COVID-19 vaccine are not currently eligible for this booster. The FDA recommends that they complete the three-dose series.
SLEEP DEPRIVATION COULD REDUCE VACCINE ANTIBODIES, NEW STUDY FOUND
The FDA said in its announcement that the Pfizer-BioNTech COVID-19 Vaccine, Bivalent includes an mRNA component that provides a “broadly protective” immune response against COVID-19, as well as against the omicron variants BA.4 and BA.5.
The Food and Drug Administration (FDA) has authorized a single booster dose of the Pfizer-BioNTech COVID-19 bivalent vaccine for children six months through four years of age who…
